. 2015 Jun;27(3):309–317. doi: 10.3978/j.issn.1000-9604.2015.06.01

Table 4. Comparison of studies assessing utility of preoperative CA125 and/or HE4 to predict OD.

Study	No. of stage III and IV	Age (year)^a	OD rate (%)	Item	Cut-off value	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	AUC
Chi et al. (6)	277^b	62	80	CA125	500 U/mL	45	64	83	23	No area calculated
Vorgias et al. (7)	426^c	62	41.5	CA125	500 U/mL	78.5	89.6	85	85	No area calculated
Angioli et al. (8)	57^d	59	63.2	CA125	414 U/mL	58	84	80	51	0.68
Angioli et al. (8)	57^d	59	63.2	HE4	262 pmol/L	86	89	93	77	0.86
Barlow et al. (9)	164^e	58	47	CA125	500 U/mL	66	59	64	36	0.67
Tang et al.	90	55	48	CA125	500 U/mL	80	40	59	65	0.60
Tang et al.	90	55	48	HE4	473 pmol/L	81	56	61	73	0.72

^a, median; ^b, ovarian cancer 232, tube cancer 9 and peritoneal carcinoma 36 (stage III 233, stage IV 44); ^c, ovarian cancer stage III and IV only; ^d, ovarian cancer only; ^e, ovarian cancer stage III and IV only; HE4, human epididymis protein 4; OD, optimal debulking; PPV, positive predictive value; NPV, negative predictive value; AUC, area under the curve.